Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen (NASDAQ:AXGN)

Core Insights - Axogen, Inc. (AXGN) reported strong Q3 '25 results with a non-GAAP EPS of $0.12, exceeding expectations by $0.05 [1] - The company's revenue reached $60.1 million, reflecting a year-over-year increase of approximately 23.7% and surpassing estimates by $3.2 million [1] Company Overview - Axogen specializes in biotechnology, focusing on innovative solutions for nerve repair and regeneration [1] - The company has a strong foundation in scientific research, which informs its investment and analytical strategies [1] Financial Performance - Non-GAAP EPS of $0.12 indicates robust profitability and effective cost management [1] - Revenue growth of 23.7% year-over-year highlights the company's expanding market presence and demand for its products [1]